Sirnaomics Ltd. (2257.HK)

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G, STP145G, and STP146G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement diseases; STP152G to treat amyloidosis; STP705 for fat reduction; STP237G and STP251G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was incorporated in 2007 and is headquartered in Germantown, Maryland.